A288330 Stock Overview
A clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bridge Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,050.00 |
| 52 Week High | ₩6,100.00 |
| 52 Week Low | ₩1,464.17 |
| Beta | 0.96 |
| 1 Month Change | 34.11% |
| 3 Month Change | 1.38% |
| 1 Year Change | 42.31% |
| 3 Year Change | -65.53% |
| 5 Year Change | -74.60% |
| Change since IPO | -73.15% |
Recent News & Updates
Shareholder Returns
| A288330 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -18.3% | -4.0% | -2.1% |
| 1Y | 42.3% | 16.1% | -9.0% |
Return vs Industry: A288330 exceeded the KR Biotechs industry which returned 16.1% over the past year.
Return vs Market: A288330 exceeded the KR Market which returned -9% over the past year.
Price Volatility
| A288330 volatility | |
|---|---|
| A288330 Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A288330's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A288330's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 36 | James Jungkue Lee | bridgebiorx.com |
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade.
Bridge Biotherapeutics, Inc. Fundamentals Summary
| A288330 fundamental statistics | |
|---|---|
| Market cap | ₩226.60b |
| Earnings (TTM) | -₩29.77b |
| Revenue (TTM) | ₩1.08m |
Over9,999x
P/S Ratio-6.9x
P/E RatioIs A288330 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A288330 income statement (TTM) | |
|---|---|
| Revenue | ₩1.08m |
| Cost of Revenue | ₩16.34m |
| Gross Profit | -₩15.25m |
| Other Expenses | ₩29.75b |
| Earnings | -₩29.77b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -590.47 |
| Gross Margin | -1,412.50% |
| Net Profit Margin | -2,756,154.64% |
| Debt/Equity Ratio | 0% |
How did A288330 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 15:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bridge Biotherapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ha Young Kang | DAOL Investment & Securities Co., Ltd. |
| Taehee Kim | Mirae Asset Securities Co., Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |